All In Biotech

Drug Trial Radar · NCT01720602

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B

Last checked: Nov 20, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Nov 2012

Primary completion

Mar 2015

Study completion Jan 2020

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Nov 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.

Conditions

  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer

Interventions

  • vorinostatDrug

    Given PO

  • anastrozoleDrug

    Given PO

  • letrozoleDrug

    Given PO

  • exemestaneDrug

    Given PO

  • positron emission tomographyProcedure

    Correlative studies

  • F-18 16 alpha-fluoroestradiolRadiation

    Correlative studies

  • fludeoxyglucose F 18Radiation

    Correlative studies

  • laboratory biomarker analysisOther

    Correlative studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Clinical Benefit of Patients Receiving Vorinostat/AI Combination Therapy According to RECISTTime frame: 8 weeks
  2. Response Rate According to RECISTTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.